subject area of

• A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor  Academic Article
• A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors  Academic Article
• A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activityin vivo  Academic Article
• ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling  Academic Article
• Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism  Academic Article
• Activation of epidermal growth factor receptor by metal-ligand complexes decreases levels of extracellular amyloid beta peptide  Academic Article
• Activation of the Ras/Mitogen-Activated Protein Kinase Pathway by Kinase-Defective Epidermal Growth Factor Receptors Results in Cell Survival but Not Proliferation  Academic Article
• Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study  Academic Article
• An A13 Repeat within the 3'-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression  Academic Article
• Analysis of Grb7 Recruitment by Heregulin-activated erbB Receptors Reveals a Novel Target Selectivity for erbB3  Academic Article
• Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity  Academic Article
• Antibodies specifically targeting a locally misfolded region of tumor associated EGFR  Academic Article
• Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells  Academic Article
• Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478  Academic Article
• Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17  Academic Article
• Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations  Academic Article
• Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer  Academic Article
• CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor  Academic Article
• Cetuximab for the Treatment of Colorectal Cancer  Academic Article
• Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate  Academic Article
• Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody  Academic Article
• Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma  Academic Article
• Colon Cancer Cells Adhesion and Spreading on Autocrine Laminin-10 Is Mediated by Multiple Integrin Receptors and Modulated by EGF Receptor Stimulation  Academic Article
• Combination osimertinib and gefitinib in C797S and T790M EGFR- mutated non–small cell lung cancer  Academic Article
• Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials  Academic Article
• Control of glioblastoma tumorigenesis by feed-forward cytokine signaling  Academic Article
• Control of mammary stem cell function by steroid hormone signalling  Academic Article
• Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients  Academic Article
• Cost-Minimization Analysis of the Treatment of Patients With Metastatic Colorectal Cancer in Greece  Academic Article
• De novo activating epidermal growth factor mutations (EGFR ) in small-cell lung cancer  Comment
• Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy  Academic Article
• Determining the limit of detection of surface bound antibody  Academic Article
• Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers  Academic Article
• Differential regulation of protein tyrosine kinase signalling by Dock and the PTP61F variants  Academic Article
• Digital PCR of genomic rearrangements for monitoring circulating tumour DNA  Conference Paper
• Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature  Academic Article
• Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer  Academic Article
• EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma  Academic Article
• EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinoma  Academic Article
• EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer  Academic Article
• Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study  Academic Article
• Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR  Academic Article
• Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478  Conference Paper
• Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development  Academic Article
• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer  Academic Article
• Epidermal growth factor receptor: mechanisms of activation and signalling  Academic Article
• Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines  Academic Article
• Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer  Academic Article
• First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma  Academic Article
• Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics  Academic Article
• Geminin and Brahma act antagonistically to regulate EGFR–Ras–MAPK signaling in Drosophila  Academic Article
• Gene expression profiling of localized prostate cancer: Getting answers to the questions that really matter  Letter
• Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer  Academic Article
• Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis  Academic Article
• Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts  Academic Article
• Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor  Academic Article
• HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer  Academic Article
• Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells  Academic Article
• High rates of albuminuria but not of low eGFR in urban Indigenous Australians: The DRUID study  Academic Article
• High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies  Academic Article
• Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor  Academic Article
• Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using 124I-IMP-R4-Labeled Antibody ch806  Academic Article
• In Reply to Leone  Letter
• Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database  Academic Article
• Internalization, Intracellular Trafficking, Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody  Academic Article
• K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer  Academic Article
• Ligand binding induces a conformational change in epidermal growth factor receptor dimers  Academic Article
• Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma  Academic Article
• MAb 806 Enhances the Efficacy of Ionizing Radiation in Glioma Xenografts Expressing the de2-7 Epidermal Growth Factor Receptor  Academic Article
• Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis  Academic Article
• Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart  Academic Article
• Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR  Academic Article
• Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene  Academic Article
• Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking  Academic Article
• Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells  Academic Article
• Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer  Academic Article
• Overexpression of multiple oncogenes related to histological grade of astrocytic glioma  Academic Article
• Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors  Academic Article
• PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab  Academic Article
• PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer  Academic Article
• Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase  Academic Article
• Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial  Academic Article
• Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components  Academic Article
• Rat epidermal growth factor: complete amino acid sequence. Homology with the correspondence murine and human proteins; isolation of a form truncated at both ends with full in vitro biological activity  Academic Article
• Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non–Small Cell Lung Cancer (NSCLC)  Academic Article
• Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway  Academic Article
• Surface Adsorbed Antibody Characterization Using ToF-SIMS with Principal Component Analysis and Artificial Neural Networks  Academic Article
• Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor  Academic Article
• Systemic treatment of colorectal cancer  Academic Article
• Targeted therapy for metastatic colorectal cancer  Academic Article
• Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization  Academic Article
• Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy  Academic Article
• Targeting the ERBB family in cancer: Couples therapy  Academic Article
• Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer  Academic Article
• Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment  Academic Article
• The EGFRvIII variant in glioblastoma multiforme  Academic Article
• The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization  Academic Article
• The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers  Academic Article
• The Phosphoprotein StarD10 Is Overexpressed in Breast Cancer and Cooperates with ErbB Receptors in Cellular Transformation  Academic Article
• The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases  Academic Article
• The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer  Academic Article
• The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor  Academic Article
• The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma  Academic Article
• The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered  Academic Article
• The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials  Academic Article
• The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR  Academic Article
• Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas  Academic Article
• Therapeutic efficacy of177Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy  Academic Article
• Therapeutic targeting of the epidermal growth factor receptor in human cancer  Academic Article
• Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity  Academic Article